Last checked at 
20 Sep 2021 07:00
LEI: 549300Q7EXQQH6KF7Z84
20 SEPTEMBER 2021
RTW Venture Fund Limited
(the "Company")
ISSUE OF EQUITY
On 17 September 2021, the Company issued 2,590,105 new ordinary shares of no par value each (consisting of 2,512,856 shares at a price of US$1.92 and 77,249 shares at £1.39 per share. These shares rank pari passu with the existing ordinary shares in issue. The issue price equates to a premium to the net asset value per share at the time of the transaction.
As a result of this issue, the total number of ordinary shares in issue now stands at 212,389,138 and the total number of voting rights in the Company is 212,389,138. There are no shares held in treasury.
The above figure of 212,389,138 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company confirms that application for admission will be made to London Stock Exchange plc and it is expected that admission will occur at 8:00 a.m. on 24 September 2021.
Stephanie Sirota, who is a Director of the Company, subscribed for 236,996 New shares. Following this subscription she will hold 1,000,000 shares representing c 0.47% of the enlarged issued ordinary share capital of the Company.
For further information, please contact:
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225-8885
J.P. Morgan Cazenove +44 (0) 20 7742 4000
William Simmonds
James Bouverat (Sales)
Barclays +44 (0) 20 7623 2323
Tom Swerling
Andrew Tusa
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.